Company intelligence / Profile preview
Amzell B.V.
Hoofddorp, Netherlandsamzell.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AMZ001 (osteoarthritis) completed Phase 2 clinical trial with results presented at OARSI World Congress 2020. AMZ002 (infantile epileptic disease) has entered Phase 3 clinical trials in the U.S. as of November 2021. AMZ004 (nausea and vomiting in pregnancy) was planned for Phase 1 clinical study in 2021.
- Therapeutic areas
- RheumatologyWomen's HealthNeurology
- Modalities
- Small moleculessynthetic polypeptidestransdermal formulations
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Amring Pharmaceuticals Inc.Ferring Pharmaceuticals
Beyond the preview
Go deeper on Amzell B.V..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amzell B.V..